5a14
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ''' | + | ==Human CDK2 with type II inhibitor== |
- | + | <StructureSection load='5a14' size='340' side='right' caption='[[5a14]], [[Resolution|resolution]] 2.00Å' scene=''> | |
- | + | == Structural highlights == | |
- | + | <table><tr><td colspan='2'>[[5a14]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A14 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5A14 FirstGlance]. <br> | |
- | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=LQ5:1-[4-(2-AZANYLPYRIMIDIN-4-YL)OXYPHENYL]-3-[4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL]UREA'>LQ5</scene></td></tr> | |
- | + | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr> | |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5a14 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5a14 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=5a14 RCSB], [http://www.ebi.ac.uk/pdbsum/5a14 PDBsum]</span></td></tr> | |
- | [[Category: | + | </table> |
- | [[Category: | + | == Function == |
- | [[Category: | + | [[http://www.uniprot.org/uniprot/CDK2_HUMAN CDK2_HUMAN]] Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.<ref>PMID:10499802</ref> <ref>PMID:11051553</ref> <ref>PMID:10995386</ref> <ref>PMID:10995387</ref> <ref>PMID:10884347</ref> <ref>PMID:11113184</ref> <ref>PMID:15800615</ref> <ref>PMID:18372919</ref> <ref>PMID:20147522</ref> <ref>PMID:20079829</ref> <ref>PMID:20935635</ref> <ref>PMID:20195506</ref> <ref>PMID:19966300</ref> <ref>PMID:21262353</ref> <ref>PMID:21596315</ref> <ref>PMID:21319273</ref> <ref>PMID:17495531</ref> |
- | [[Category: | + | == References == |
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Alexander, L T]] | ||
+ | [[Category: Bountra, C]] | ||
+ | [[Category: Carpenter, E P]] | ||
+ | [[Category: Cowan-Jacob, S W]] | ||
+ | [[Category: Edwards, A M]] | ||
+ | [[Category: Elkins, J M]] | ||
[[Category: Fedorov, O]] | [[Category: Fedorov, O]] | ||
[[Category: Knapp, S]] | [[Category: Knapp, S]] | ||
- | [[Category: | + | [[Category: Kopec, J]] |
[[Category: Krojer, T]] | [[Category: Krojer, T]] | ||
- | [[Category: Bountra, C]] | ||
- | [[Category: Carpenter, E.P]] | ||
- | [[Category: Szklarz, M]] | ||
[[Category: Moebitz, H]] | [[Category: Moebitz, H]] | ||
- | [[Category: | + | [[Category: Pike, A C.W]] |
- | [[Category: Savitsky, P | + | [[Category: Savitsky, P A]] |
- | [[Category: | + | [[Category: Szklarz, M]] |
+ | [[Category: Cdk2]] | ||
+ | [[Category: Cyclin]] | ||
+ | [[Category: Inhibitor]] | ||
+ | [[Category: Kinase]] | ||
+ | [[Category: Transferase]] | ||
+ | [[Category: Type ii]] |
Revision as of 14:19, 22 July 2015
Human CDK2 with type II inhibitor
|
Categories: Alexander, L T | Bountra, C | Carpenter, E P | Cowan-Jacob, S W | Edwards, A M | Elkins, J M | Fedorov, O | Knapp, S | Kopec, J | Krojer, T | Moebitz, H | Pike, A C.W | Savitsky, P A | Szklarz, M | Cdk2 | Cyclin | Inhibitor | Kinase | Transferase | Type ii